Results 101 to 110 of about 737 (141)

A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes. [PDF]

Sci Rep
Zhu Z, Chen Q, Wang Z, Chen Q, Li X, Liu Y, Lu H, Feng J, Xie M, Dong X, Chen B, Huang J, Zeng X, Zeng Z, Yuan Y, Xu F, Liao X, Liang B, Chen W.   +18 more
europepmc   +1 more source

Commentary: A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes. [PDF]

Front Endocrinol (Lausanne)
Guo S, Zhang J, Shu J.
europepmc   +1 more source

Association of Azvudine with severe outcomes among hospitalized patients with COVID-19 during an omicron-dominance period in Wuhan, China: a single-center, retrospective, matched cohort study. [PDF]

BMC Infect Dis
Guo Z, Li W, Wang K, Lu Y, Gao S, Wang X, Zhao Y, Zhai Z, Chen B, Sun F, Zhao S, Cheng H.   +11 more
europepmc   +1 more source

An IRES-like cis-acting element located within the EV-A71 coding region drives translation independent of the 5'-IRES and modulates viral fitness through regulated binding of viral RNA to 3D polymerase. [PDF]

J Virol
Xing Y, Liu Q, Fu M, Zheng H, Zhao T, Chen X, Cai X, Long J-E.   +7 more
europepmc   +1 more source

Editorial: Toxicity mechanisms, exposure, toxicokinetic and risk assessment aspects of metals, toxic for animals and humans, volume III. [PDF]

Front Pharmacol
Zhu Y, El Demerdash FM, Yang X, Machado MM, Boye A, Sun X.   +5 more
europepmc   +1 more source

Factors Influencing COVID-19 Viral Clearance: Implications for Vaccination and Antiviral Therapy. [PDF]

Infect Drug Resist
Zeng J, Xu H, Luo S, Zhou X, Li X, Zeng Y, Wang Y, Jiang H, Lin C, Zheng C, Ruan J, Yu W, Yao J, Zhao J.   +13 more
europepmc   +1 more source

Editorial: Emerging concepts for respiratory viruses after the pandemic. [PDF]

Front Cell Infect Microbiol
Dimopoulou D, Skevaki C, Can F, Morfin-Sherpa F, Fragkou PC.   +4 more
europepmc   +1 more source

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID-19: A Propensity Score-Matched Analysis. [PDF]

Infect Drug Resist
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L.   +6 more
europepmc   +1 more source

A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine. [PDF]

Infect Drug Resist
Yu X, Luo R, Xie G, Ji J, Wang J, Li X, Qian X, Wang X.   +7 more
europepmc   +1 more source